Govt Moots Plan To Curtail Spurious Drugs Menace

Image
BUSINESS STANDARD
Last Updated : Jan 28 2013 | 1:08 AM IST

The government has come up with a list of recommendations for the pharmaceutical industry to combat the menace of manufacture and sale of spurious drugs.

A committee was constituted by the ministry of health and family welfare under the chairmanship of S P Agarwal, director general health services, to study the issue.

It consisted of representatives from the pharmaceutical industry, state drugs regulatory authorities, Central Drugs Standard Organisation, All India Organisation of Chemists and Druggists (AIOCD), Organisation of Pharmaceutical Producers of India (OPPI) and the Indian Drugs Manufacturers Association (IDMA).

Also Read

The committee recommended that each state should set up an intelligence-cum-legal cell and anti-spurious squads under the supervision of a senior officer for investigation and should follow up cases of spurious drugs.

The state drugs control authorities should employ watchers or decoy customers for purchasing samples of drugs and for keeping a watch over the movement of suspected drugs. The committee report also suggests that the pharmaceutical industry, through its associations, should play an active role in combating the menace. A checklist should be prepared for the guidance of the manufacturers and retailers to identify and distinguish between the spurious and genuine products.

The committee recommends that the AIOCD should develop its mechanism in identifying the persons directly or indirectly involved in abetting the distribution of spurious drugs or drugs of questionable quality. The checklist prepared for the guidance of the members should be widely published by AIOCD.

There should also be a discrete watch over units which have become sick or whose licenses have been cancelled as such places are prone to becoming centres for the manufacture of spurious or counterfeited drugs.

Also, training programmes need to be conducted for officers of the drug control administration in matters concerning development of intelligence, detection, investigation and preparation of filing of complaints and court procedures.


*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 07 2002 | 12:00 AM IST

Next Story